XPO1 inhibition in KRAS-mutant cancers: time for clinical trials but how?

Transl Lung Cancer Res. 2025 Aug 31;14(8):2895-2899. doi: 10.21037/tlcr-2025-432. Epub 2025 Aug 13.

Authors

Misako Nagasaka¹, Husain Y Khan², Faustine Luo¹, Mohammed Najeeb Al-Hallak², Muhammad Wasif Saif², Ramzi M Mohammad², Asfar S Azmi²

Affiliations

¹ University of California Irvine School of Medicine, Orange, CA, USA.
² Department of Oncology, Wayne State University School of Medicine, Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA.

No abstract available

Keywords: KRAS inhibitors; eltanexor; non-small cell lung cancer (NSCLC); nuclear export; selinexor.

Publication types

Editorial
Comment